Skip to content

Trial · Observational

CompletedPhase not statedRegistry data

The Differential Effects of Diabetes Therapy on Inflammation

NCTNCT02150707 (opens ClinicalTrials.gov in a new tab)Other idDPP4201401
Open at ClinicalTrials.govAsk about this trial

Overview

Status
Completed
Phase
Phase not stated
Enrollment
17 participants (actual)
Sponsor
University College Dublin · Other
Design
Not stated
Countries
1 country

Ireland

Start
May 2014
Primary completion
Dec 2015
Completion
Dec 2015
First posted
30 May 2014 (estimated)
Last update posted
18 May 2016 (estimated)
Conditions
Diabetic Nephropathy · Type 2 Diabetes

Timeline

1 trial · 1 completed

  • Completed
  • Ongoing
  • Not yet recruiting
  • Stopped
  • Estimated dates (est.)
  • Results posted
201420152016
  1. Ph –

    The Differential Effects of Diabetes Therapy on Inflammation

    NCT02150707

    May 2014 to Dec 2015

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

This study aims to determine if different diabetes treatments have different effects on inflammation; in particular, kidney inflammation. This type of inflammation is common in people with diabetes, and can lead to kidney failure. This study will investigate the effect of different types of diabetes treatment on kidney inflammation. This will help us to decide if certain types of medicine should be preferred in people with evidence of inflammation in their kidneys, as this may help prevent major complications including kidney failure.

Interventions

  • Dipeptidyl-Peptidase IV InhibitorsDrug
  • Glucagon-Like Peptide 1Drug

Arms2

  • Other

    Dipeptidyl-Peptidase IV Inhibitors

    Newly started on DPP4 inhibitor for hyperglycaemia

  • Other

    Glucagon-Like Peptide 1

    Newly started on GLP-1 for hyperglycaemia or obesity

Primary outcomes1

Outcomes the sponsor listed as primary.

  1. Monocyte:chemoattractant protein 1 (MCP-1):creatinine ratio

    Time frame · 6 months

Secondary outcomes(1)

  1. Albumin:creatinine ratio

    Time frame · 6 months

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

No results are posted for this trial.

Completed trials do not always post results.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies1

Studies that cite this trial.

Studies with results

1 study on this page

Indexing hint: Randomized controlled trial · 2011

11 results

Effect of exenatide on inflammatory and oxidative stress markers in patients with type 2 diabetes mellitus.

Wu et al. 2011Diabetes technology & therapeuticscited by 71

PMID 21284481DOI 10.1089/dia.2010.0048PUB-21284481

Full text at the publisher11 results
Publisher pageSee results (11)

Eligibility

Who could join, as posted.

Sex
All
Age
from 30 Years
Healthy volunteers
Not accepted
Inclusion and exclusion criteria, as posted
Inclusion Criteria: * Age over 30 years * Diagnosis of type 2 diabetes for one year or more * Diagnosis of DKD as defined by two distinct albumin:creatinine ratio measurements above the gender specific range in the local reference laboratory with an interval of no less than eight week between measurements * Stable dose of an inhibitor of the renin angiotensin system for a period of 8 weeks Exclusion Criteria: * Any cognitive impediment that preclude the participant from giving free and informed consent * Substance abuse including alcohol excess * Use of a GLP-1 analogue in the last 6 months * Pregnancy * Hypersensitivity to the prescribed treatment

PepBank is a research reference. Talk to a doctor before you use any peptide.